Navigation Links
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Date:11/15/2011

gn and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 


'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
2. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
3. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
4. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
5. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
6. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
7. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Molecular Devices Launches the MicroMax Low Volume Microplate, the Highest Throughput Low Volume Solution Available
10. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
11. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 2010 Phytomedics, Inc., a transformational healthcare company ... products solely derived from plant sources, announced today ... the amount of $244,000 under the Qualifying Therapeutic ... of its lead product PMI-001 for Rheumatoid Arthritis. ...
... Nov. 9, 2010 NewCardio, Inc. (OTC Bulletin Board: ... announced today that Dr. Samuel George, NewCardio,s Senior Medical ... a blinded "testing" dataset, conducted independently by the Cardiac ... to be held on December 9, 2010, at the ...
Cached Medicine Technology:Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , TONBRIDGE, England, Sept. 17 ... the past 150 years, by leading figures in the drugs industry. ... light bulb and penicillin in a star-studded competition organised to celebrate ... four inventions went head-to-head in a live debate, with top industry ...
... , , LOUISVILLE, Ky., Sept. 14 ... products, is proud to announce the MEGAcel(TM) I filter ... Helior media used in the MEGAcel I filter ... conventional micro-fiberglass media. With a significantly lower operating resistance, energy consumption is less ...
... , MIDDLETOWN, Conn., Sept. 17 As ... Blue Shield Foundation grant to the national American Diabetes Association ... the "Family Link" program here in Connecticut. , ... connects parents of children with diabetes with parent "mentors"; offers ...
... ... recently named to the advisory board for PerfectServe, a healthcare communications company. , ... Knoxville, TN (PRWEB) September ... a healthcare communications company. The board provides guidance on innovative ways to leverage PerfectServe,s ...
... , , , ... Foundation of America (AFA) today applauded Senate Finance Committee Chairman ... the provision, for including cognitive impairment screening for Medicare beneficiaries ... 2009." , , AFA had ...
... , DALLAS, Sept. 17 For the ... Health Harris Methodist Hospital Southlake (THHMHS) one of the country,s 100 ... from an evaluation of 317 healthcare companies in partnership with Best ... programs nationwide. , , "Our vision ...
Cached Medicine News:Health News:Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 2Health News:AAF(R) Announces MEGAcel(TM) I Filter with Helior(TM) Media 2Health News:Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Association's 'Family Link' Program In Connecticut 2Health News:Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Association's 'Family Link' Program In Connecticut 3Health News:Robert Fanning Named to PerfectServe Advisory Board 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Proposal 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Proposal 3Health News:Modern Healthcare Selects Texas Health Harris Methodist Hospital Southlake as One of the Best Places to Work in Healthcare 2
... supports are a convenient, reusable, patient-friendly ... for common orthopedic conditions/instabilities. These products ... compression and lateral to medial influence ... the skin and soft tissue structures. ...
... the medial or lateral compartment for relief ... we equipped this unique brace with our ... suitable for post-op and long-term rehab [>4weeks] ... , ,Indications: , Medial or ...
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
... of the TROM provides the same easy ... as the full foam TROM, but is ... of use and versatility of the Cool ... following major ligament surgery, meniscal repairs, patella ...
Medicine Products: